🟢 Ocugen is trading 5% up today after provisional OCU400 approval in The Bahamas

Ocugen is trading 5% higher at $1.05 after announcing provisional approval and priority designation in The Bahamas for OCU400, its investigational retinitis pigmentosa gene therapy.

• The company plans to provide OCU400 through an expanded access program.
• It aims to treat the first patient within 90 days after full regulatory approval. MarketWatch reported that shares ticked higher following the announcement.